Table 5.
Subsequent COVID-19 vaccination.
| Patients with CNS inflammatory event, n = 38 a | |
|---|---|
| Received subsequent COVID-19 vaccine, n (%) | |
| Yes | 16/34 (47.1) |
| No | 18/34 (52.9) |
| Outcome following subsequent COVID-19 vaccine, n (%) | |
| No adverse events | 14/16 (87.5) |
| New or recurrent neurological symptoms | 2/16 (12.5) |
| Symptom recrudescence | 1/16 (6.3) |
| Unknown | 1/16 (6.3) |
Abbreviations: CNS = central nervous system.
a
Not available for all patients, with sample size shown for each variable based on available data.